The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Aberrant wound-healing responses to injury have been implicated in the development of pulmonary fibrosis, but the mediators directing these pathologic responses have yet to be fully identified. We show that lysophosphatidic acid levels increase in bronchoalveolar lavage fluid following lung injury in the bleomycin model of pulmonary fibrosis, and that mice lacking one of its receptors, LPA1, are markedly protected from fibrosis and mortality in this model. The absence of LPA1 led to reduced fibroblast recruitment and vascular leak, two responses that may be excessive when injury leads to fibrosis rather than to repair, whereas leukocyte recruitment was preserved during the first week after injury. In persons with idiopathic pulmonary fibrosis, lysophosphatidic acid levels in bronchoalveolar lavage fluid were also increased, and inhibition of LPA1 markedly reduced fibroblast responses to the chemotactic activity of this fluid. LPA1 therefore represents a new therapeutic target for diseases in which aberrant responses to injury contribute to fibrosis, such as idiopathic pulmonary fibrosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bexotegrast is a small molecule dual inhibitor of αvβ6 and αvβ1[105]. Cumulative data of 630 patients composed of several phase 1 and 2 trials investigating αvβ6 and αvβ1 in both IPF and primary sclerosing cholangitis demonstrated mild adverse effects in the bexotegrast group (headache, diarrhea, and nausea), with diarrhea being the most common in phase 2 studies”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [104]
In the citing paper
“In pulmonary fi brosis, lysophosphatidic acid receptor 1 (LPA1) activation is associated with fi broblast recruitment, activation/proliferation, and survival, as well as epithelial cell apoptosis, all of which drive lung fi brosis progression (8, 9).”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
In the citing paper
“LPA1 is known to be involved in in fl ammatory responses of vascular endothelium and fi broblast recruitment”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
In the citing paper
“and LPA1 de fi ciency attenuated fi broblast recruitment in a murine model of lung fi brosis (8).”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
Citations
Cites
Wound Healing--Aiming for Perfect Skin Regeneration
Martin, P. (1997) · Science · doi:10.1126/science.276.5309.75 · Cited by 4,804 · cited 1×
“After cutaneous injury, fibroblasts migrate into the provisional fibrin matrix of the wound clot during granulation tissue formatio”
BackgroundRidley, A. J., & Hall, A. (1992) · Cell · doi:10.1016/0092-8674(92)90163-7 · Cited by 4,468
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Chemokines — Chemotactic Cytokines That Mediate Inflammation
Luster, A. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380706 · Cited by 3,630 · cited 1×
“1a ), indicating that the relevant fibroblast receptor(s) signal through the Gα i class of G proteins, a hallmark of the chemoattractant subfamily of GPCR”
BackgroundSelf-citationMunger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
The epigenetic progenitor origin of human cancer
Feinberg, A. P., Ohlsson, R., & Henikoff, S. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1748 · Cited by 1,853 · cited 1×
“Epigenetic processes, such as DNA or histone methylation and histone acetylation, produce heritable but potentially reversible changes in DNA or its associated proteins, and are prominent in developmental processes and oncogenesis ( 1 ).”
BackgroundSelman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786 · cited 1×
“In the lung, aberrant wound-healing responses to injury are thought to contribute to the pathogenesis of idiopathic pulmonary fibrosis (IPF”
BackgroundSelf-citationCirculating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., & Cerami, A. (1994) · Molecular Medicine · doi:10.1007/bf03403533 · Cited by 1,308
Kim, K. K., Kugler, M. C., Wolters, P. J., Robillard, L., Galvez, M. G., Brumwell, A. N., Sheppard, D., & Chapman, H. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605669103 · Cited by 1,257 · cited 1×
“Fibrin deposition in injured airspaces may contribute to fibroblast accumulation both by providing a provisional matrix for fibroblast migration and by promoting epithelial-to-mesenchymal transitio”
BackgroundThe emerging role of lysophosphatidic acid in cancer
Mills, G. B., & Moolenaar, W. H. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1143 · Cited by 1,094 · cited 1×
“LPA has been shown to induce the invasion of cancer cells across tissue barriers, promoting metastasi”
Background
Cited by
Items 701–800 of 857
Molyneaux, P. L., & Spagnolo, P. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202410-2018ed · Cited by 2
Advance Genome Disorder Prediction Model Using Deep Learning Algorithms
Ponmalar, S., Priyadharshini, K., Pooja, V., & Swathi, M. (2024) · International Conference for Innovation in Technology (INOCON) · doi:10.1109/inocon60754.2024.10511618 · Cited by 1
Autotaxin concentrations in peritoneal dialysis effluent reflect peritoneal function
Horikoshi, K., Sakai, N., Oshima, M., Yamauchi, H., Ikeda, M., Hayashi, K., Yanagisawa, H., Yamamori, F., Kajikawa, S., Hayashi, D., et al. (2024) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.14211 · Cited by 2
Ha, A. W., Sudhadevi, T., Jafri, A., Mayer, C., MacFarlane, P. M., Natarajan, V., & Harijith, A. K. (2024) · Pediatric Research · doi:10.1038/s41390-024-03610-9 · Cited by 1
Wang, H., Liu, Y., Xu, Q., Lin, G., Shao, L., Mo, J., Li, J., Chu, Z., & Ma, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117769 · Cited by 2
Wu, Y., & Ou, T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00048-2 · Cited by 1
Liu, Y., Chen, X., Liu, M., Yuan, J., Li, Q., Li, L., Dong, Q., Tao, J., Shen, F., & Xiao, C. (2025) · FASEB BioAdvances · doi:10.1096/fba.2025-00128 · Cited by 1
“Tager [27] et al. revealed that in the bleomycin-induced mouse pulmonary fibrosis experiment, the lung fibrosis of mice with LPAR1 gene deficiency was significantly mitigated.”
Tachibana, S., Ogawa, H., Ichimura‐Shimizu, M., Takayama, T., Bando, H., Sato, S., Inoue, K., Kurano, M., Nishioka, Y., & Tsuneyama, K. (2025) · Allergology International · doi:10.1016/j.alit.2025.11.011 · Cited by 1
Kim, K. D., & Yoo, B. C. (2026) · Biomolecules · doi:10.3390/biom16030465 · Cited by 1
“Sustained LPA receptor signaling has been implicated in pathological contexts such as fibrosis [30,31], vascular remodeling [26], thrombosis [29], and tumor progression [32–34].”
InfluentialMansour, G. K., Hajjar, A. W., & Sukkarieh, H. H. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1748453 · Cited by 1
“Genetic deletion of LPAR1 in mice provided powerful preclinical validation, demonstrating significant protection from bleomycin-induced pulmonary fibrosis (43).”
Condorelli, G. A., Genova, R., Bonifacio, D., & Dragostin, O. M. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118005 · Cited by 1
Lysophospholipid Mediators: Their Receptors and Synthetic Pathways
Kano, K., Makide, K., Ishiguro, J., Yukiura, H., Aikawa, S., Uwamizu, A., Shinjo, Y., Namiki, K., Kawana, H., Nemoto, S., et al. (2015) · Springer eBooks · doi:10.1007/978-4-431-55669-5_8 · Cited by 1
Autotaxin Inhibitors in Fibrosis
Desroy, N., & Heckmann, B. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788015783-00117 · Cited by 1
LPA Receptor Subtypes LPA 1 and LPA 2 as Potential Drug Targets
Bain, G., & Seiders, T. J. (2013) · Wiley eBooks · doi:10.1002/9781118531426.ch32 · Cited by 1
Autotaxin: A Unique Ecto‐Type Pyrophosphodiesterase with Diverse Functions
Yukiura, H., & Aoki, J. (2013) · Wiley eBooks · doi:10.1002/9781118531426.ch6 · Cited by 1
Investigative Approaches to Drug Therapy
Ong, V. H., & Denton, C. P. (2011) · Springer eBooks · doi:10.1007/978-1-4419-5774-0_50 · Cited by 1
Lysophosphatidic acid as a potential trigger of atrial fibrillation
Wei, Y. Q., Liu, S., Zhao, L., Zhou, G., Chen, S., & Li, H. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.08.001 · Cited by 1
“the contribution of the LPA/LPA receptor-1 pathway to pulmonary fibrosis in vivo [11].”
BackgroundZebrafish as a Model Animal for Studying Lysophosphatidic Acid Signaling
Aoki, J., & Yukiura, H. (2015) · Springer eBooks · doi:10.1007/978-4-431-55669-5_14 · Cited by 1
Maher, T. M., & Spagnolo, P. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10006615 · Cited by 1
Tando, Y., Ota, C., Yamada, M., Kamata, S., Yamaya, M., Kano, K., Okudaira, S., Aoki, J., & Kubo, H. (2015) · Transplantation Direct · doi:10.1097/txd.0000000000000542 · Cited by 1
“In particular, LPA is involved in the onset of fibrosis in the kidney(8) and lung.(9,10) As mentioned above, immunosuppression therapy is ineffective at the onset of OB.”
BackgroundFibroblast biology in idiopathic pulmonary fibrosis
Horowitz, J. C., & Thannickal, V. J. (2015) · doi:10.2217/fmeb2013.13.205 · Cited by 1
Commission de Recherche Translationnelle de la Société de Réanimation de Langue Française, Guillon, A., Gibot, S., Ait‐Oufella, H., Uhel, F., Monneret, G., Sharshar, T., Taccone, F. S., Textoris, J., Tamion, F., et al. (2017) · Médecine Intensive Réanimation · doi:10.1007/s13546-017-1279-7 · Cited by 1
“Ainsi, dans des modèles murins d'agression pulmonaire, l'inhibition de la migration des fibroblastes diminue les lésions de fibrose et améliore la survie [16] .”
BackgroundDenton, C. P., & Lafyatis, R. (2011) · Springer eBooks · doi:10.1007/978-1-4419-5774-0_24 · Cited by 1
The FLORA study: presenting a novel IPF trial design
Crestani, B., & Günther, A. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30269-8 · Cited by 1
Challenges of Translation of Anti-Fibrotic Therapies into Clinical Practice in IBD
Rogler, G. (2018) · Springer eBooks · doi:10.1007/978-3-319-90578-5_20 · Cited by 1
Epigenetic Regulators of Inflammatory Gene Expression
Kaur, S., Mishra, J., Sehrawat, A., Bhatti, G. K., Navik, U., Reddy, P. H., & Bhatti, J. S. (2023) · Springer eBooks · doi:10.1007/978-981-99-4780-5_4 · Cited by 1
Cellular and Molecular Mechanisms of Fibrosis in Systemic Sclerosis
Trojanowska, M., Varga, J., & Lagares, D. (2024) · Springer eBooks · doi:10.1007/978-3-031-40658-4_18 · Cited by 2
Emerging Targets for the Treatment of Idiopathic Pulmonary Fibrosis
Lucas, M. C., & Budd, D. C. (2013) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-417150-3.00011-9 · Cited by 1
Sakai, N., & Tager, A. M. (2013) · Inflammation and Regeneration · doi:10.2492/inflammregen.33.078 · Cited by 1
Self-citationControl of analgesic and anti-inflammatory pathways by fatty acid amide hydrolase
Long, J. H. (2012) · Cited by 1
Scleroderma Associated Interstitial Lung Disease
Castelino, F. V., & Steen, V. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00016-0 · Cited by 1
The role of GPR87 in Pulmonary FibrosisPreprint
Khoury, J., Ahangari, F., Adams, T. S., Justet, A., Manning, E. P., McDonough, J. E., Bärnthaler, T., Anderson, S., Nikola, F., Beermann, M. L., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.10.617569 · Cited by 1
Yan, J., Han, L., Ba, X., Shen, P., Lin, W., Li, T., Zhang, R., Yang, Y., Li, Y., Li, C., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6597839/v1 · Cited by 1
The role of LPA in kidney pathologies
Mirzoyan, K. (2017) · theses.fr (ABES) · doi:10.70675/199e35d9zaecez4e02z9482z06ece5aca70d · Cited by 1
“Genetic deletion of LPA1 receptors as well as pharmacologic blockade with the LPA1 specific antagonists AM095 or AM966 or with the LPA1/LPA3 receptor antagonists VPC12249 or Ki16425 reduces collagen deposition and fibroblast accumulation, decreases expression of TGF-β1, α-SMA, CTGF and protects against lung fibrosis i…”
BackgroundRubio-Gordón, L., Martinez-Perez, C., Cristóbal, R. S., Dávalos, A., Guallar‐Castillón, P., Rangel-Zúñiga, O. A., Costeira, R., Rodríguez‐Artalejo, F., López‐Miranda, J., Bell, J. T., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10225367/v1 · Cited by 1
d’Audigier, C. (2013) · theses.fr (ABES) · doi:10.70675/19800b70z5208z47c4z97e8z80d335c3a541
Beauchemin, K. (2009) · Papyrus : Institutional Repository (Université de Montréal) · doi:10.71781/31392
Lysophospholipid Regulation of Lung Fibrosis
Shea, B. S., & Tager, A. M. (2013) · Wiley eBooks · doi:10.1002/9781118531426.ch27
Self-citationGlobal Gene Expression Program of Lysophosphatidic Acid (LPA)‐Stimulated Fibroblasts
Stortelers, C., & Moolenaar, W. H. (2013) · Wiley eBooks · doi:10.1002/9781118531426.ch3
Lysophosphatidic Acid (LPA) Signaling and Cardiovascular Pathology
Smyth, S. S., Dong, A., Wheeler, J., Panchatcharam, M., & Morris, A. J. (2013) · Wiley eBooks · doi:10.1002/9781118531426.ch13
Escaping growth arrest in cancer
Kortlever, R. M. (2008) · Utrecht University Repository (Utrecht University)
Patel, R. B. (2010) · The Knowledge Bank (The Ohio State University)
Fantozzi, E. T. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2013.tde-15032014-102321 · Cited by 4
Kieselmann, O. (2011) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-16989
van Wijk, X. M. R. (2013) · Radboud Repository (Radboud University)
Aaltonen, N. (2013) · UEF eRepo (University of Eastern Finland)
Autotaxin signaling, purinergic receptors and lung damage
(2015) · Inflammation and Cell Signaling · doi:10.14800/ics.1092
“In literature surveys bleomycin stands out as the first low-molecular weight xenobiotic shown to induced the ATX-LPA axis ([23]).”
BackgroundOga, T., Handa, T., Mishima, M., Chin, K., & Narumiya, S. (2013)
Cheng, H. (2009) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/kfq4-gv83
Priapism in Sickle Cell Disease: New Aspects of Pathophysiology
Claudino, M. A., Franco‐Penteado, C. F., & Fertrin, K. Y. (2016) · Springer eBooks · doi:10.1007/978-3-319-06713-1_11
PPAP2B EXPRESSION LIMITS LESION FORMATION IN MURINE MODELS OF ATHEROSCLEROSIS
Mueller, P. A. (2016) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2016.299
“LPA binds to any one of its six known GPCRs (LPA16) and elicits a multitude of responses in nearly every cell type studied [10, 11, 21, 24, 26, 84, 151-153].”
BackgroundFuture Directions in Basic and Clinical Science
Mikacenic, C. R., & Raghu, G. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_21
PROAGIO (A Protein Designed to Target Integrin ?V?3)
Turaga, R. C. (2017) · Digital Archive @ GSU · doi:10.57709/10416467
The Design and Synthesis of Autotaxin Inhibitors and Analogs of Lysophosphatidic Acid
Gupte, R. (2011) · doi:10.21007/etd.cghs.2011.0121 · Cited by 1
Clinical Spectrum and Pulmonary Manifestations of Patients with Anti U1RNP Antibody Status.
Thilagavathi, N. (2014)
Regulation of lysophosphatidate-induced mechanisms of chemo-resistance
Venkatraman, G. (2015) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3bn9x79k
Detection of Lysophosphatidic Acid in Serum; Towards a Cost Effective Test for Ovarian Cancer
Franier, D. L., & James, B. P. (2017) · TSpace (University of Toronto)
Kato, K., & Nureki, O. (2018) · Nihon Kessho Gakkaishi · doi:10.5940/jcrsj.60.142
The Autotaxin - Lysophosphatidic Acid Axis as a Novel Therapeutic Target for Liver Fibrosis
Booijink, R. S., & Bansal, R. (2019) · OBM Hepatology and Gastroenterology · doi:10.21926/obm.hg.1902024
Morphological and functional studies in a sheep model of pulmonary fibrosis
Dewage, V., & Nimanthi, S. (2020) · Minerva Access (University of Melbourne)
Metastatic cancer: How one can address the therapeutic challenge
Jain, S., Raza, K., Agrawal, A. K., & Vaidya, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817846-1.00023-0
Targeting Molecular and Cellular Mechanisms in Idiopathic Pulmonary Fibrosis
Banudevi, S., & Bose, V. (2021) · Springer eBooks · doi:10.1007/978-981-33-6827-9_12
Zhou, I. Y., Montesi, S. B., Akam, E. A., & Caravan, P. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816386-3.00077-6
Charest, P. G. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.717956615.793461222
Interaction Between Epithelial and Mesenchymal Cells in Interstitial Lung Disease
Cohen, M., & Wolters, P. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11657-5
Bryant, A. J. (2015) · Respiratory medicine · doi:10.1007/978-3-319-23998-9_6
Sandbo, N. K. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_7
Stubbs, J. R. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737389609.793572183
Baltera, B. (2011) · Nature Biotechnology · doi:10.1038/nbt.2034
Faculty Opinions recommendation of Unifying mechanism for different fibrotic diseases.
Migliaccio, A. R. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727535500.793564986
Dynamics of regulatory T cells in lung transplant patients
de Silva, A. T. A. (2022) · Queensland University of Technology · doi:10.5204/thesis.eprints.230504
Ma, H., Wu, X., Li, Y., & Xia, Y. (2022) · Kompass Neumología · doi:10.1159/000526906
Pulmonary Fibrosis: One Manifestation, Various Diseases
Ruaro, B., Matucci‐Cerinic, M., Baratella, E., Confalonieri, M., Salton, F., & Hughes, M. (2022) · Frontiers research topics · doi:10.3389/978-2-83250-654-7
Nguyen, L. P., Khan, R. A., Kang, S., Lee, H., Hwang, J., & Kim, H. (2023) · ACS Omega · doi:10.1021/acsomega.3c04798
Role of autotaxin for the pathogenesis of liver fibrosis in biliary atresia
Udomsinprasert, W. (2016) · Chula Digiverse · doi:10.58837/chula.the.2016.1693
Rôle de l'axe ATX/LPA dans le remodelage osseux
Demesmay-Michaud, L. (2022) · theses.fr (ABES) · doi:10.70675/91849ed6z7e5bz4d58z8364ze70b295a046f
Asano, Y., & Distler, J. H. W. (2024) · Springer eBooks · doi:10.1007/978-3-031-40658-4_19
Anwendung von Organometallkatalysatoren in der API-Synthese
Basu, D., Achanta, S., Kumar, N. U., Budhdev, R. R., & Bandichhor, R. (2024) · Springer eBooks · doi:10.1007/978-3-031-52858-3_4
Affinity of Nintedanib Towards New Candidate Target for Idiopathic Pulmonary Fibrosis
Balasubramanian, H. B., Biswas, S., Talmon, M., Patrucco, F., Balbo, P. E., Fresu, L. G., & Bagchi, A. (2024) · Borneo Journal of Pharmacy · doi:10.33084/bjop.v7i3.7218 · Cited by 1
Andresen, B. T. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103610
“Moreover, because LPA levels increase in bleomycin-induced IPF (Tager et al, 2008), the bleomycin-induced IPF is an excellent model to test the hypothesis that ACT-1016-0707 is superior to a reversible antagonist, such as admilparant in the treatment of IPF.”
Li, J., Jiang, N., Zhang, J., Ma, D., Tan, Z., & Zhai, X. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.143578
Lin, J., Wang, S., Cao, L., Wang, L., Li, J., Tang, N., Jiao, C., Ma, J., Zhao, X., & Zhang, H. (2026) · Inflammation · doi:10.21203/rs.3.rs-7509054/v1
Wuyts, W. A., Bonella, F., Ishii, H., Lee, J. S., Renzoni, E. A., Hadl, S., Krzykalla, J., Stowasser, S., Engel, M., & Molina‐Molina, M. (2025) · ERJ Open Research · doi:10.1183/23120541.00973-2025
Li, S.-C., Lin, Y., Hsiao, C., & Lee, S. (2025) · Developmental Biology · doi:10.1016/j.ydbio.2025.12.005
The genetic contribution to stroke in northern Sweden
Janunger, T. (2010)
Yoon, D., Choi, B., Kim, J.-E., Kim, E.-Y., Chung, S.-H., Min, H.-J., Sung, Y., Chang, E.-J., & Song, J.-K. (2024) · Figshare · doi:10.6084/m9.figshare.25415009
Wang, J., Sun, Y., Teng, S., & Li, K. (2020) · Figshare · doi:10.6084/m9.figshare.12127575
Szóstek-Mioduchowska, A. Z., Leciejewska, N., Zelmańska, B., Staszkiewicz‐Chodor, J., Ferreira-Dias, G. M., & Skarzynski, D. (2020) · Figshare · doi:10.6084/m9.figshare.12972286
Imani, J., Bodine, S. P., Lamattina, A. M., Ma, D. D., Shrestha, S., Maynard, D., Bishop, K. S., Nwokeji, A., Malicdan, M. C. V., Testa, L. C., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20154304
Li, Q., Wong, W., Birnberg, A., Chakrabarti, A., Yang, X., Choy, D. F., Olsson, J. K., Verschueren, E., Neighbors, M., Sandoval, W., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16674917
Yoon, D., Choi, B., Kim, J.-E., Kim, E.-Y., Chung, S.-H., Min, H.-J., Sung, Y., Chang, E.-J., & Song, J.-K. (2024) · Figshare · doi:10.6084/m9.figshare.25414832
Nathan, S., Zhang, H., Andreoli, M., Leopold, P. L., & Crystal, R. G. (2021) · Figshare · doi:10.6084/m9.figshare.14361560
Xue, C., Wu, N., Fan, Y., Ma, J., & Ye, Q. (2021) · Figshare · doi:10.6084/m9.figshare.14234943
Szóstek-Mioduchowska, A. Z., Leciejewska, N., Zelmańska, B., Staszkiewicz‐Chodor, J., Ferreira-Dias, G. M., & Skarzynski, D. (2020) · Figshare · doi:10.6084/m9.figshare.12972283
Yoon, D., Choi, B., Kim, J.-E., Kim, E.-Y., Chung, S.-H., Min, H.-J., Sung, Y., Chang, E.-J., & Song, J.-K. (2024) · Figshare · doi:10.6084/m9.figshare.26693500
Huang, W.-C., Chuang, C.-F., Huang, Y.-T., Chung, I.-C., Chen, M.-L., Chuang, T.-Y., Yang, X.-L., Chou, Y.-Y., Liu, C.-H., Chen, N.-Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24564126
Wu, X., Gou, H., Ou, Z., Qiu, H., Liu, H., Fu, Z., & Chen, L. (2022) · Figshare · doi:10.6084/m9.figshare.21258279
The role of galectin-3 in the development of idiopathic pulmonary fibrosis
Parmar, N. R. (2019) · Nottingham ePrints (University of Nottingham) · Cited by 1
Tsiri, P., Kouvela, M., Παπαϊωάννου, Ο., Sotiropoulou, V., Katsaras, M., Syrigos, N. K., Sampsonas, F., & Tzouvelekis, A. (2026) · Life · doi:10.3390/life16020295 · Cited by 1
“Elevated LPA drives fibroblast activation and vascular leakage in experimental fibrosis [69], while the auto-taxin/LPA axis has recently been implicated in lung cancer proliferation and metastasis [70], suggesting a shared lipid-mediated pathway supporting fibrosis and tumorigenesis.”
Metadata
- Authors
- Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., Hart, W. K., Pardo, A., Blackwell, T. S., Xu, Y., Chun, J., & Luster, A. D.
- Affiliations
- Harvard University (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Indiana University Indianapolis (US)
- Vanderbilt University (US)
- Universidad Nacional Autónoma de México (MX)
- Scripps Research Institute (US)
- Corresponding author
- Luster, Andrew D
- ORCID
- Venue
- Nature Medicine
- Published
- 2007-12-09
- Volume
- 14
- Issue
- 1
- Pages
- 45-54
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2131032222
- Cited by
- 823
- References
- 54
- Citations by year
- 2026: 24 · 2025: 49 · 2024: 50 · 2023: 49 · 2022: 51 · 2021: 61 · 2020: 55 · 2019: 38 · 2018: 36 · 2017: 47 · 2016: 49 · 2015: 41 · 2014: 51 · 2013: 49 · 2012: 53
- FWCI
- 23.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Lung Association
- National Institutes of Health (5r01ca069212-18)
- National Institute of Mental Health (K02 MH01723, R01MH051699, K02MH001723, R01MH-51699)
- National Cancer Institute (R01CA69212, R01-CA89228, R01CA095042, R01CA089228)
- National Institute of Neurological Disorders and Stroke (R01NS048478)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lysophosphatidic acid, LPA1 receptor, pulmonary fibrosis, idiopathic pulmonary fibrosis, lung injury, fibroblast recruitment, vascular leakage, bleomycin-induced fibrosis, bronchoalveolar lavage fluid, wound healing, chemotaxis, therapeutic target
- MeSH terms
- Animals, Bleomycin, Bronchoalveolar Lavage Fluid, Female, Fibroblasts, Leukocytes, Lung, Lysophospholipids, Male, Mice, Inbred C57BL, Models, Biological, Pulmonary Fibrosis, Mice, Knockout, Receptors, Lysophosphatidic Acid, Mice, Lung Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.